Skip to main content
Premium Trial:

Request an Annual Quote

UPDATE: Cytogen Sets Up $70M Credit Line to Support Research

This story has been updated from a previous version.

NEW YORK, Oct 10 - Biopharmaceutical company Cytogen announced Tuesday that it had reached a deal with Acqua Wellington North American Equities Fund for an equity financing facility of up to $70 million.

“This is a line of credit that we can use at our discretion,” said Richard Krawiec, head of investor relations and corporate communications at Cytogen. “In the future we can put stock to them and they have to buy it.”

Krawiec said that Acqua Wellington would receive a discount on the stock, but he declined to be specific about the size of the discount.

Krawiec said the company had established the line of credit in order to make funds available to acquire new products, to accelerate activity at its AxCell subsidiary, a company that is developing a protein pathway database, and to finance clinical trials of its vaccine for prostate cancer.

The company expects to begin clinical trials of the vaccine early next year.

Cytogen of Princeton, NJ currently has 76 million shares outstanding, which does not include the three million shares it has made available for sale via a shelf registration in the spring. If the company decides to sell more than three million shares to Acqua Wellington or to another investor it would have to register to do so.

Recently, Cytogen received $6 million in net proceeds from an equity placement of 902,601 shares of registered common stock with Acqua Wellington. Based on those figures, Acqua Wellington paid $6.65 a share.

Shares of Cytogen, which have been falling since September, were up 7/32, or 3.9 percent, at 5 7/8 in afternoon trading on the Nasdaq.

Acqua Wellington Asset Management is the advisor to the Acqua Wellington Family of Funds, which focus on the technology and life science sectors.  

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.